His comments come after Pfizer announced on Wednesday that its vaccine was highly effective at preventing COVID-19 infection in kids aged 12 to 15 in a late-stage trial of more than 2,000 participants.
Pfizer said it plans to submit the data to the US Food and Drug Administration and the European Medicines Agency to request for emergency authorization of the vaccine.
-Squawk Box (@SquawkCNBC) March 31, 2021
Pfizer CEO Albert Bourla said: "We plan to submit these data to FDA as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year."